(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
4 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 8.55%
@ $50.17
発行日: 27 4月 2024 @ 04:33
リターン: -0.62%
前回のシグナル: 4月 26 - 22:30
前回のシグナル:
リターン: -0.18 %
Live Chart Being Loaded With Signals
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases...
Stats | |
---|---|
本日の出来高 | 959 841 |
平均出来高 | 1.32M |
時価総額 | 6.01B |
EPS | $0 ( 2024-02-27 ) |
次の収益日 | ( $-0.550 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -11.20 |
ATR14 | $2.13 (4.27%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | Sullivan Timothy Eugene | Sell | 14 164 | Common Stock |
2024-04-18 | Sullivan Timothy Eugene | Buy | 14 164 | Common Stock |
2024-04-12 | Dunlop A. Sinclair | Buy | 1 500 | Common Stock |
2024-04-12 | Dunlop A. Sinclair | Sell | 1 500 | Stock Option (Right to Buy) |
2024-04-08 | Deschatelets Pascal | Buy | 69 107 | Common Stock |
INSIDER POWER |
---|
2.41 |
Last 100 transactions |
Buy: 1 047 810 | Sell: 959 444 |
ボリューム 相関
Apellis Pharmaceuticals 相関
10 最も正の相関 | |
---|---|
BRIVU | 0.949 |
MSDAU | 0.948 |
TIOAU | 0.945 |
VLAT | 0.945 |
NVCN | 0.945 |
INZY | 0.945 |
LDHA | 0.943 |
GVCI | 0.941 |
ALXN | 0.941 |
TIOA | 0.94 |
10 最も負の相関 | |
---|---|
NDRA | -0.967 |
MNPR | -0.95 |
DFFN | -0.948 |
ENLV | -0.947 |
MMAT | -0.945 |
LSAQ | -0.945 |
JG | -0.942 |
ATNF | -0.942 |
MAGS | -0.941 |
ASRV | -0.938 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Apellis Pharmaceuticals 相関 - 通貨/商品
Apellis Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $396.59M |
総利益: | $336.38M (84.82 %) |
EPS: | $-4.45 |
FY | 2023 |
収益: | $396.59M |
総利益: | $336.38M (84.82 %) |
EPS: | $-4.45 |
FY | 2022 |
収益: | $75.42M |
総利益: | $69.79M (92.53 %) |
EPS: | $-6.15 |
FY | 2021 |
収益: | $66.56M |
総利益: | $61.36M (92.19 %) |
EPS: | $-8.84 |
Financial Reports:
No articles found.
Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。